A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.

Inclusion Criteria:Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021Evidence of active cancerAt least 1 claim for apixaban or low molecular weight heparin (LMWH)Age 18 years or olderExclusion Criteria:diagnosis of atrial fibrillation/flutterprocedure for mechanical heart valve or inferior vena cava filterVTE diagnosis in the baseline periodanticoagulant therapy in the baseline periodpregnancy